Vestal Point Capital LP Sells 15,000 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Vestal Point Capital LP decreased its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 810,000 shares of the biopharmaceutical company's stock after selling 15,000 shares during the quarter. Xenon Pharmaceuticals makes up approximately 1.9% of Vestal Point Capital LP's holdings, making the stock its 21st largest holding. Vestal Point Capital LP owned about 1.06% of Xenon Pharmaceuticals worth $31,752,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the company. FMR LLC raised its position in shares of Xenon Pharmaceuticals by 8.8% during the fourth quarter. FMR LLC now owns 7,525,290 shares of the biopharmaceutical company's stock worth $294,991,000 after acquiring an additional 607,606 shares during the last quarter. Braidwell LP increased its position in Xenon Pharmaceuticals by 7.6% in the fourth quarter. Braidwell LP now owns 2,913,964 shares of the biopharmaceutical company's stock worth $114,227,000 after purchasing an additional 206,709 shares during the period. Janus Henderson Group PLC raised its holdings in Xenon Pharmaceuticals by 12.3% during the 4th quarter. Janus Henderson Group PLC now owns 2,866,755 shares of the biopharmaceutical company's stock worth $112,425,000 after purchasing an additional 314,363 shares during the last quarter. Polar Capital Holdings Plc raised its holdings in Xenon Pharmaceuticals by 10.3% during the 4th quarter. Polar Capital Holdings Plc now owns 2,697,657 shares of the biopharmaceutical company's stock worth $105,748,000 after purchasing an additional 253,012 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its position in Xenon Pharmaceuticals by 1.3% during the 4th quarter. Alliancebernstein L.P. now owns 1,443,180 shares of the biopharmaceutical company's stock valued at $56,573,000 after purchasing an additional 18,445 shares during the period. Institutional investors and hedge funds own 95.45% of the company's stock.

Xenon Pharmaceuticals Stock Performance

NASDAQ:XENE traded up $0.03 on Thursday, reaching $30.49. The company's stock had a trading volume of 1,889,419 shares, compared to its average volume of 520,946. Xenon Pharmaceuticals Inc. has a 1-year low of $26.74 and a 1-year high of $46.00. The business's 50-day moving average price is $33.83 and its two-hundred day moving average price is $37.74. The firm has a market cap of $2.34 billion, a PE ratio of -10.81 and a beta of 1.21.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.07. The business had revenue of $7.50 million during the quarter, compared to analyst estimates of $1.64 million. During the same quarter in the prior year, the firm posted ($0.62) earnings per share. As a group, sell-side analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Analyst Ratings Changes

XENE has been the subject of several analyst reports. Needham & Company LLC lowered their price target on shares of Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Evercore ISI assumed coverage on shares of Xenon Pharmaceuticals in a research note on Wednesday, May 14th. They issued an "outperform" rating and a $55.00 price objective on the stock. Wells Fargo & Company lowered their target price on shares of Xenon Pharmaceuticals from $50.00 to $47.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th. Chardan Capital reiterated a "buy" rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, May 13th. Finally, Wall Street Zen downgraded Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Wednesday. One research analyst has rated the stock with a sell rating and twelve have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $54.82.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.